# Dr. Chae-Yong Kim

Type: Person

Source: Healthcare Intelligence Brief — https://gethealthbrief.com/entity/dr-chae-yong-kim
Canonical HTML page: https://gethealthbrief.com/entity/dr-chae-yong-kim

## Timeline

- **2026-06-15**: Press Release Issued — Rznomics announces the presentation and key findings via PRNewswire, making the data public to investors and the biomedical community.
- **2026-06-13**: Interim Data Presentation at ASNO 2026 — Dr. Chae-Yong Kim of Seoul National University Bundang Hospital delivers oral presentation on interim Phase 1/2a results of RZ-001 in recurrent glioblastoma, reporting safety and early efficacy signals.

## Recent coverage (1 stories)

### RZ-001 Gene Therapy Shows >6-Month Disease Control in rGBM; 10 Patients Treated with No Safety Concerns
2026-07-27 02:59:47 · Sentiment: Bullish · Impact: 6/10 · Sources: 2

Rznomics' RNA-based gene therapy RZ-001 demonstrates encouraging interim safety and efficacy in recurrent glioblastoma, with no dose-limiting toxicities and prolonged disease control in a Phase 1/2a trial presented at ASNO 2026.
Full story: https://gethealthbrief.com/story/rz001-gene-therapy-rgbm-6-month-disease-control

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://gethealthbrief.com/guides/methodology for the full editorial methodology.